Charles River Laboratories International, Inc. (NYSE: CRL) today
reported its results for the first quarter of 2008. For the
quarter, net sales increased 16.0% to $337.7 million from $291.2
million in the first quarter of 2007. Both the Research Models and
Services (RMS) and Preclinical Services (PCS) business segments
reported strong sales growth, driven by demand for our broad
portfolio of essential drug discovery and development products and
services, as pharmaceutical and biotechnology companies invested in
basic research and increased their strategic use of outsourced drug
development services. Foreign exchange contributed 4.2% to the net
sales growth. On a GAAP basis, net income for the first quarter of
2008 was $45.2 million, or $0.64 per diluted share, compared to
$36.8 million, or $0.54 per diluted share, for the first quarter of
2007. The first quarter of 2007 included a loss from discontinued
operations of $0.5 million. On a non-GAAP basis, net income was
$50.8 million for the first quarter of 2008, compared to $43.2
million for the same period in 2007, an increase of 17.6%.
First-quarter diluted earnings per share on a non-GAAP basis were
$0.72, an increase of 12.5% compared to $0.64 per share in the
first quarter of 2007. Non-GAAP earnings per share in the first
quarter of 2008 excluded $7.6 million of amortization of intangible
assets related to acquisitions and a charge of $0.7 million related
to the Company�s disposition of its legacy Preclinical Services
facility in Worcester, Massachusetts. For the first quarter of
2007, non-GAAP results excluded $7.9 million of amortization of
intangible assets and stock-based compensation related to
acquisitions and a charge of $0.8 million related to the exit of
the Worcester facility. James C. Foster, Chairman, President and
Chief Executive Officer, said, �The year is off to a very strong
start, with double-digit organic sales growth, excluding foreign
exchange, in both of our business segments. We are continuing to
see robust demand from pharmaceutical and biotechnology customers
for the essential products and services that we provide, as they
endeavor to discover new therapies and increasingly adopt strategic
outsourcing as a more efficient and cost effective means of drug
development. As a result of our aggressive investment to expand and
strengthen our infrastructure, we are extremely well-positioned to
meet our clients� needs, and our position as a leading provider of
products and services for drug development is reflected in our
first-quarter financial results. Based on these results and the
continuing strength of demand for our broad portfolio of products
and services, we are today reaffirming our 2008 guidance.� Research
Models and Services (RMS) Sales for the RMS segment were $168.6
million in the first quarter of 2008, an increase of 17.8% from
$143.1 million in the first quarter of 2007. Sales growth was broad
based, with strong global demand from pharmaceutical and
biotechnology companies for research models and services, as well
as Endotoxin and Microbial Detection (formerly In Vitro) products.
In the first quarter of 2008, the RMS segment�s GAAP operating
margin increased to 33.1% compared to 32.9% in the first quarter of
2007, with the improvement due primarily to higher sales. On a
non-GAAP basis, which excluded charges of $0.5 million for
acquisition-related amortization, the operating margin was 33.4%
compared to 33.1% for the same period in the prior year. Non-GAAP
results in the first quarter of 2007 excluded $0.4 million of
amortization related to acquisitions. Preclinical Services (PCS)
First-quarter net sales for the PCS segment were $169.1 million, an
increase of 14.1% from $148.1 million in the first quarter of 2007.
Continuing strong demand for general and specialty toxicology
services from pharmaceutical and biotechnology customers was the
primary factor which contributed to the sales growth. As expected,
the additional costs associated with the transition to the new
preclinical facility in Nevada and the negative impact of foreign
exchange in Canada resulted in lower operating margins for the PCS
segment. The first-quarter GAAP operating margin declined to 13.8%
from 15.8% in the same period in the prior year. On a non-GAAP
basis, which excludes $7.0 million of acquisition-related
amortization and a charge of $0.7 million associated with the
Company�s disposition of its Worcester, Massachusetts facility, the
operating margin declined to 18.3% from 21.4% in the first quarter
of 2007. 2008 Guidance The Company reaffirms its forward-looking
guidance for 2008, which was originally provided on December 12,
2007. The guidance for GAAP earnings per diluted share now includes
the following items, which have been excluded from non-GAAP diluted
earnings per share: A gain of approximately $0.04 per diluted share
due to the Company�s decision in the second quarter of 2008 to
curtail its U.S. defined benefit pension plan and a charge of
approximately $0.01-$0.02 per diluted share related to the
Company�s disposition of its legacy Preclinical Services facility
in Worcester, Massachusetts. 2008 GUIDANCE � Net sales growth (in
%) 10% - 13% GAAP EPS estimate $2.59 - $2.69 Amortization of
intangible assets $0.30 Gain on curtailment of U.S. defined benefit
pension plan ($0.04) Charges related to preclinical facility
disposition $0.01-$0.02 Non-GAAP EPS estimate $2.87 - $2.97 Webcast
Charles River Laboratories has scheduled a live webcast on
Wednesday, May 7, at 8:30 a.m. ET to discuss matters relating to
this press release. To participate, please go to ir.criver.com and
select the webcast link. You can also find the associated slide
presentation and reconciliations of non-GAAP financial measures to
comparable GAAP financial measures on the website. Use of Non-GAAP
Financial Measures This press release contains non-GAAP financial
measures, such as non-GAAP earnings per diluted share from
continuing operations, which exclude amortization of intangible
assets and other charges related to our acquisitions, charges
related to the disposition of our Worcester facility, and gains
attributable to the curtailment of our U.S. pension plan. We
exclude these items from the non-GAAP financial measures because
they are outside our normal operations. There are limitations in
using non-GAAP financial measures, as they are not prepared in
accordance with generally accepted accounting principles, and may
be different than non-GAAP financial measures used by other
companies. In particular, we believe that the inclusion of
supplementary non-GAAP financial measures in this press release
helps investors to gain a meaningful understanding of our core
operating results and future prospects without the effect of
one-time charges, and is consistent with how management measures
and forecasts the Company's performance, especially when comparing
such results to prior periods or forecasts. We believe that the
financial impact of our acquisitions is often large relative to our
overall financial performance, which can adversely affect the
comparability of our results on a period-to-period basis. In
addition, certain activities, such as business acquisitions, happen
infrequently and the underlying costs associated with such
activities do not recur. Non-GAAP results also allow investors to
compare the Company�s operations against the financial results of
other companies in the industry who similarly provide non-GAAP
results. The non-GAAP financial measures included in this press
release are not meant to be considered superior to or a substitute
for results of operations prepared in accordance with GAAP. The
Company intends to continue to assess the potential value of
reporting non-GAAP results consistent with applicable rules and
regulations. Reconciliations of the non-GAAP financial measures
used in this press release to the most directly comparable GAAP
financial measures are set forth in the text of this press release,
and can also be found on the Company�s website at ir.criver.com.
Caution Concerning Forward-Looking Statements This news release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as
�anticipate,� �believe,� �expect,� �will,� �may,� �estimate,�
�plan,� �outlook,� and �project� and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These statements also include
statements regarding our projected 2008 earnings; the future demand
for drug discovery and development products and services, including
the outsourcing of these services; the impact of specific actions
intended to improve overall operating efficiencies and
profitability; the timing of the opening of new and expanded
facilities; future cost reduction activities by our customers; and
Charles River�s future performance as delineated in our
forward-looking guidance, and particularly our expectations with
respect to sales growth. Forward-looking statements are based on
Charles River�s current expectations and beliefs, and involve a
number of risks and uncertainties that are difficult to predict and
that could cause actual results to differ materially from those
stated or implied by the forward-looking statements. Those risks
and uncertainties include, but are not limited to: a decrease in
research and development spending, a decrease in the level of
outsourced services, or other cost reduction actions by our
customers; the ability to convert backlog to sales; special
interest groups; contaminations; industry trends; new displacement
technologies; USDA and FDA regulations; changes in law; continued
availability of products and supplies; loss of key personnel;
interest rate and foreign currency exchange rate fluctuations;
changes in tax regulation and laws; changes in generally accepted
accounting principles; and any changes in business, political, or
economic conditions due to the threat of future terrorist activity
in the U.S. and other parts of the world, and related U.S. military
action overseas. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
February 20, 2008, as well as other filings we make with the
Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and
events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation
and expressly disclaims any duty to update information contained in
this news release except as required by law. About Charles River
Accelerating Drug Development. Exactly. Charles River provides
essential products and services to help pharmaceutical and
biotechnology companies, government agencies and leading academic
institutions around the globe accelerate their research and drug
development efforts. Our more than 8,500 employees worldwide are
focused on providing clients with exactly what they need to improve
and expedite the discovery, development through first-in-human
evaluation, and safe manufacture of new therapies for the patients
who need them. To learn more about our unique portfolio and breadth
of services, visit www.criver.com. CHARLES RIVER LABORATORIES
INTERNATIONAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED) (dollars in thousands, except for per share data) � �
Three Months Ended March 29,2008 March 31,2007 � Total net sales $
337,685 $ 291,199 Cost of products sold and services provided �
207,308 � � 175,626 � Gross margin 130,377 115,573 Selling, general
and administrative 59,306 53,017 Amortization of intangibles �
7,571 � � 7,855 � Operating income 63,500 54,701 Interest income
(expense) (666 ) (2,059 ) Other income (expense) � (837 ) � 149 �
Income before income taxes and minority interests 61,997 52,791
Provision for income taxes � 16,926 � � 15,310 � Income before
minority interests 45,071 37,481 Minority interests � 83 � � (254 )
Income from continuing operations 45,154 37,227 Loss from
discontinued businesses, net of tax � - � � (464 ) Net income $
45,154 � $ 36,763 � � Earnings (loss) per common share Basic:
Continuing operations $ 0.67 $ 0.56 Discontinued operations $ - $
(0.01 ) Net income $ 0.67 $ 0.55 Diluted: Continuing operations $
0.64 $ 0.55 Discontinued operations $ - $ (0.01 ) Net income $ 0.64
$ 0.54 � Weighted average number of common shares outstanding Basic
67,504,848 66,346,152 Diluted 70,559,456 67,632,780 CHARLES RIVER
LABORATORIES INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE
SHEETS (UNAUDITED) (dollars in thousands) � � � March 29,2008
December 29,2007 Assets Current assets Cash and cash equivalents $
239,876 $ 225,449 Trade receivables, net 239,385 213,908
Inventories 90,881 88,023 Other current assets 75,309 79,477
Current assets of discontinued businesses � 638 � 1,007 Total
current assets 646,089 607,864 Property, plant and equipment, net
788,218 748,793 Goodwill, net 1,122,011 1,120,540 Other
intangibles, net 143,184 148,905 Deferred tax asset 83,897 89,255
Other assets 57,141 85,993 Long-term assets of discontinued
businesses � 4,187 � 4,187 Total assets $ 2,844,727 $ 2,805,537 �
Liabilities and Shareholders� Equity Current liabilities Current
portion of long-term debt $ 33,743 $ 25,051 Accounts payable 36,772
36,715 Accrued compensation 36,805 53,359 Deferred revenue 97,556
102,021 Accrued liabilities 69,743 61,366 Other current liabilities
27,480 23,268 Current liabilities of discontinued businesses � 738
� 748 Total current liabilities 302,837 302,528 Long-term debt
476,367 484,998 Other long-term liabilities � 152,024 � 154,044
Total liabilities � 931,228 � 941,570 Minority interests 3,473
3,500 Total shareholders� equity � 1,910,026 � 1,860,467 Total
liabilities and shareholders� equity $ 2,844,727 $ 2,805,537
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SELECTED BUSINESS
SEGMENT INFORMATION (UNAUDITED) (dollars in thousands) � � � Three
Months Ended March 29,2008 March 31,2007 Research Models and
Services Net sales $ 168,596 $ 143,068 Gross margin 76,256 63,654
Gross margin as a % of net sales 45.2 % 44.5 % Operating income
55,813 47,021 Operating income as a % of net sales 33.1 % 32.9 %
Depreciation and amortization 6,659 5,569 Capital expenditures
10,146 7,084 � Preclinical Services Net sales $ 169,089 $ 148,131
Gross margin 54,121 51,919 Gross margin as a % of net sales 32.0 %
35.0 % Operating income 23,268 23,444 Operating income as a % of
net sales 13.8 % 15.8 % Depreciation and amortization 15,674 14,344
Capital expenditures 29,558 30,840 � � Unallocated Corporate
Overhead $ (15,581 ) $ (15,764 ) � � Total Net sales $ 337,685 $
291,199 Gross margin 130,377 115,573 Gross margin as a % of net
sales 38.6 % 39.7 % Operating income 63,500 54,701 Operating income
as a % of net sales 18.8 % 18.8 % Depreciation and amortization
22,333 19,913 Capital expenditures 39,704 37,924 CHARLES RIVER
LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (dollars in
thousands) � � � Three Months Ended March 29, 2008 March 31, 2007
Research Models and Services Net sales $ 168,596 $ 143,068
Operating income 55,813 47,021 Operating income as a % of net sales
33.1 % 32.9 % Add back: Amortization related to acquisitions � 534
� � 374 � Operating income, excluding specified charges (Non-GAAP)
$ 56,347 $ 47,395 Non-GAAP operating income as a % of net sales
33.4 % 33.1 % � Preclinical Services Net sales $ 169,089 $ 148,131
Operating income 23,268 23,444 Operating income as a % of net sales
13.8 % 15.8 % Add back: Amortization related to acquisitions 7,037
7,481 Impairment and other charges � 686 � � 819 � Operating
income, excluding specified charges (Non-GAAP) $ 30,991 $ 31,744
Non-GAAP operating income as a % of net sales 18.3 % 21.4 % � �
Unallocated Corporate Overhead $ (15,581 ) $ (15,764 ) Add back:
Stock-based compensation related to Inveresk acquisition � - � � 70
� Unallocated corporate overhead, excluding specified charges
(Non-GAAP) $ (15,581 ) $ (15,694 ) � � Total Net sales $ 337,685 $
291,199 Operating income 63,500 54,701 Operating income as a % of
net sales 18.8 % 18.8 % Add back: Amortization related to
acquisition 7,571 7,855 Stock-based compensation related to
Inveresk acquisition - 70 Impairment and other charges � 686 � �
819 � Operating income, excluding specified charges (Non-GAAP) $
71,757 $ 63,445 Non-GAAP operating income as a % of net sales 21.2
% 21.8 % � � Charles River management believes that supplementary
non-GAAP financial measures provide useful information to allow
investors to gain a meaningful understanding of our core operating
results and future prospects, without the effect of one-time
charges, consistent with the manner in which management measures
and forecasts the Company�s performance. The supplementary non-GAAP
financial measures included are not meant to be considered superior
to, or a substitute for results of operations prepared in
accordance with GAAP. The Company intends to continue to assess the
potential value of reporting non-GAAP results consistent with
applicable rules and regulations. CHARLES RIVER LABORATORIES
INTERNATIONAL, INC. RECONCILIATION OF GAAP EARNINGS TO NON-GAAP
EARNINGS (dollars in thousands, except for per share data) � �
Three Months Ended March 29, 2008 March 31, 2007 � Net income $
45,154 $ 36,763 Less: Discontinued operations � - � � 464 � Net
income from continuing operations 45,154 37,227 Add back:
Amortization related to acquisitions 7,571 7,855 Stock-based
compensation related to Inveresk acquisition - 70 Impairment and
other charges 686 819 Tax effect � (2,605 ) � (2,784 ) Net income
from continuing operations, excluding specified charges (Non-GAAP)
$ 50,806 � $ 43,187 � � Weighted average shares outstanding - Basic
67,504,848 66,346,152 Effect of dilutive securities: 2.25% senior
convertible debentures 1,421,424 - Stock options and contingently
issued restricted stock 1,363,212 1,153,912 Warrants � 269,972 � �
132,716 � Weighted average shares outstanding - Diluted �
70,559,456 � � 67,632,780 � � Basic earnings per share $ 0.67 $
0.55 Diluted earnings per share $ 0.64 $ 0.54 � Basic earnings per
share, excluding specified charges (Non-GAAP) $ 0.75 $ 0.65 Diluted
earnings per share, excluding specified charges (Non-GAAP) $ 0.72 $
0.64 � � Charles River management believes that supplementary
non-GAAP financial measures provide useful information to allow
investors to gain a meaningful understanding of our core operating
results and future prospects, without the effect of one-time
charges, consistent with the manner in which management measures
and forecasts the Company�s performance. The supplementary non-GAAP
financial measures included are not meant to be considered superior
to, or a substitute for results of operations prepared in
accordance with GAAP. The Company intends to continue to assess the
potential value of reporting non-GAAP results consistent with
applicable rules and regulations.
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jul 2023 to Jul 2024